glp-1 price drop Study: US obesity rates are dropping as use increases GLP-1 price reduction: President Trump

Several trial limitations, including the small sample size, limit the interpretation of these preliminary findings, which require validation in a larger trial

Then the body starts feeling shaky, nauseous, weak, foggy, or dizzy

While FDA does not limit compounding to drug shortages and we believe there are paths to continue offering access to certain compounded GLP-1s after the shortage ends, we cannot guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all, due to a variety of factors outside our control, including supply chain, intellectual property, regulatory and resource allocation matters.) On October 2, 2024, this risk materialized when FDA announced on its website that Lilly had resolved the tirzepatide shortage, meaning that companies making and distributing compounded copies needed to stop in their tracks, regardless of ongoing patient care

PMID: 36038016

Moreover, mice treated with teduglutide had improvements in histological morphology and crypt cell proliferation (Drucker et al